Molecular chaperones and co-chaperones in parkinson disease

Neuroscientist

Volumn 18, Issue 6, 2012, Pages 589-601

  Dimant, Hemi ^a   Ebrahimi Fakhari, Darius ^a   McLean, Pamela J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

synuclein; co chaperone; heat shock protein (Hsp); molecular chaperone; neurodegeneration; Parkinson disease

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ALPHA SYNUCLEIN; BAG 5 PROTEIN; CELASTROL; CHAPERONE; GELDANAMYCIN; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HEAT SHOCK TRANSCRIPTION FACTOR 1; ST13 PROTEIN; TANESPIMYCIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; VALPROIC ACID;

APOPTOSIS; CELL FUNCTION; CYTOTOXICITY; DISEASE ASSOCIATION; DISEASE COURSE; DOPAMINERGIC NERVE CELL; DROSOPHILA MELANOGASTER; HUMAN; LIGAND BINDING; LOSS OF FUNCTION MUTATION; MOLECULARLY TARGETED THERAPY; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN HOMEOSTASIS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SUBSTANTIA NIGRA PARS COMPACTA; TRANSCRIPTION REGULATION;

ANIMALS; HUMANS; MOLECULAR CHAPERONES; PARKINSON DISEASE; PROTEIN FOLDING;

EID: 84865861347     PISSN: 10738584     EISSN: 10894098     Source Type: Journal    
DOI: 10.1177/1073858412441372     Document Type: Review

References (92)

1. Auluck PK, Chan HY, Trojanowski JQ, Lee VM, Bonini NM. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science. 2002 ; 295 (5556). 865-8
2. Auluck PK, Meulener MC, Bonini NM. Mechanisms of suppression of {alpha}-synuclein neurotoxicity by geldanamycin in Drosophila. J Biol Chem. 2005 ; 280 (4). 2873-8
3. Bensaude O, Babinet C, Morange M, Jacob F. Heat shock proteins, first major products of zygotic gene activity in mouse embryo. Nature. 1983 ; 305 (5932). 331-3
4. Bjorklund T, Kordower JH. Gene therapy for Parkinson's disease. Mov Disord. 2010 ; 25 (Suppl 1). S161-73
5. Chai Y, Koppenhafer SL, Bonini NM, Paulson HL. Analysis of the role of heat shock protein (Hsp) molecular chaperones in polyglutamine disease. J Neurosci. 1999 ; 19 (23). 10338-47
6. Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet. 2004 ; 364 (9440). 1167-9
7. Cleren C, Calingasan NY, Chen J, Beal MF. Celastrol protects against MPTP- and 3-nitropropionic acid-induced neurotoxicity. J Neurochem. 2005 ; 94 (4). 995-1004
8. Connell P, Ballinger CA, Jiang J, Wu Y, Thompson LJ, Hohfeld J. The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nat Cell Biol. 2001 ; 3 (1). 93-6
9. Conway KA, Harper JD, Lansbury PT. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med. 1998 ; 4 (11). 1318-20
10. Cudkowicz ME, Shefner JM, Simpson E, Grasso D, Yu H, Zhang H. Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis. Muscle Nerve. 2008 ; 38 (1). 837-44
11. Danzer KM, Ruf WP, Putcha P, Joyner D, Hashimoto T, Glabe C. Heat-shock protein 70 modulates toxic extracellular alpha-synuclein oligomers and rescues trans-synaptic toxicity. FASEB J. 2011 ; 25 (1). 326-36
12. Dietz GP, Bahr M. Delivery of bioactive molecules into the cell: the Trojan horse approach. Mol Cell Neurosci. 2004 ; 27 (2). 85-131
13. Ding X, Goldberg MS. Regulation of LRRK2 stability by the E3 ubiquitin ligase CHIP. PLoS One. 2009 ; 4 (6). e5949
14. Dong Z, Wolfer DP, Lipp HP, Bueler H. Hsp70 gene transfer by adeno-associated virus inhibits MPTP-induced nigrostriatal degeneration in the mouse model of Parkinson disease. Mol Ther. 2005 ; 11 (1). 80-8
15. Ebrahimi-Fakhari D, Cantuti-Castelvetri I, Fan Z, Rockenstein E, Masliah E, Hyman BT. Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of alpha-synuclein. J Neurosci. 2011a ; 31 (41). 14508-20
16. Ebrahimi-Fakhari D, McLean PJ, Unni VK. Alpha-synuclein's degradation in vivo: opening a new. 2012 ; 8 (2). 281-3
17. Ebrahimi-Fakhari D, Wahlster L, McLean PJ. Molecular chaperones in Parkinson's disease: present and future. J Parkinsons Dis. 2011b ; 1 (4). 299-320
18. Edwards TL, Scott WK, Almonte C, Burt A, Powell EH, Beecham GW. Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson's disease. Ann Hum Genet. 2010 ; 74 (2). 97-109
19. Falsone SF, Kungl AJ, Rek A, Cappai R, Zangger K. The molecular chaperone Hsp90 modulates intermediate steps of amyloid assembly of the Parkinson-related protein alpha-synuclein. J Biol Chem. 2009 ; 284 (45). 31190-9
20. Faust K, Gehrke S, Yang Y, Yang L, Beal MF, Lu B. Neuroprotective effects of compounds with antioxidant and anti-inflammatory properties in a Drosophila model of Parkinson's disease. BMC Neurosci. 2009 ; 10: 109
21. Flower TR, Chesnokova LS, Froelich CA, Dixon C, Witt SN. Heat shock prevents alpha-synuclein-induced apoptosis in a yeast model of Parkinson's disease. J Mol Biol. 2005 ; 351 (5). 1081-100
22. Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS. Alpha-synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol. 2002 ; 4 (2). 160-4
23. Gispert-Sanchez S, Auburger G. The role of protein aggregates in neuronal pathology: guilty, innocent, or just trying to help? J Neural Transm Suppl. 2006 ;: 111-7
24. Gorman AM, Szegezdi E, Quigney DJ, Samali A. Hsp27 inhibits 6-hydroxydopamine-induced cytochrome c release and apoptosis in PC12 cells. Biochem Biophys Res Commun. 2005 ; 327 (3). 801-10
25. Hartl FU, Hayer-Hartl M. Molecular chaperones in the cytosol: from nascent chain to folded protein. Science. 2002 ; 295 (5561). 1852-8
26. Hay DG, Sathasivam K, Tobaben S, Stahl B, Marber M, Mestril R. Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach. Hum Mol Genet. 2004 ; 13 (13). 1389-405
27. Hinault MP, Cuendet AF, Mattoo RU, Mensi M, Dietler G, Lashuel HA. Stable alpha-synuclein oligomers strongly inhibit chaperone activity of the Hsp70 system by weak interactions with J-domain co-chaperones. J Biol Chem. 2010 ; 285 (49). 38173-82
28. Hohfeld J, Minami Y, Hartl FU. Hip, a novel cochaperone involved in the eukaryotic Hsc70/Hsp40 reaction cycle. Cell. 1995 ; 83 (4). 589-98
29. Hou Y, Zou J. Delivery of HSF1(+) protein using HIV-1 TAT protein transduction domain. Mol Biol Rep. 2009 ; 36 (8). 2271-7
30. Irizarry MC, Growdon W, Gomez-Isla T, Newell K, George JM, Clayton DF. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity. J Neuropathol Exp Neurol. 1998 ; 57 (4). 334-7
31. Jung AE, Fitzsimons HL, Bland RJ, During MJ, Young D. HSP70 and constitutively active HSF1 mediate protection against CDCrel-1-mediated toxicity. Mol Ther. 2008 ; 16 (6). 1048-55
32. Kalia LV, Kalia SK, Chau H, Lozano AM, Hyman BT, McLean PJ. Ubiquitinylation of alpha-synuclein by carboxyl terminus Hsp70-interacting protein (CHIP) is regulated by Bcl-2-associated athanogene 5 (BAG5). PLoS One. 2011 ; 6 (2). e14695
33. Kalia SK, Lee S, Smith PD, Liu L, Crocker SJ, Thorarinsdottir TE. BAG5 inhibits parkin and enhances dopaminergic neuron degeneration. Neuron. 2004 ; 44 (6). 931-45
34. Karpinar DP, Balija MB, Kugler S, Opazo F, Rezaei-Ghaleh N, Wender N. Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease models. EMBO J. 2009 ; 28 (20). 3256-68
35. Kiffin R, Christian C, Knecht E, Cuervo AM. Activation of chaperone-mediated autophagy during oxidative stress. Mol Biol Cell. 2004 ; 15 (11). 4829-40
36. Kim SA, Chang S, Yoon JH, Ahn SG. TAT-Hsp40 inhibits oxidative stress-mediated cytotoxicity via the inhibition of Hsp70 ubiquitination. FEBS Lett. 2008 ; 582 (5). 734-40
37. Kim YS, Alarcon SV, Lee S, Lee MJ, Giaccone G, Neckers L. Update on Hsp90 inhibitors in clinical trial. Curr Top Med Chem. 2009 ; 9 (15). 1479-92
38. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998 ; 392 (6676). 605-8
39. Klucken J, Ingelsson M, Shin Y, Irizarry MC, Hedley-Whyte ET, Frosch M. Clinical and biochemical correlates of insoluble alpha-synuclein in dementia with Lewy bodies. Acta Neuropathol. 2006a ; 111 (2). 101-8
40. Klucken J, Outeiro TF, Nguyen P, McLean PJ, Hyman BT. Detection of novel intracellular alpha-synuclein oligomeric species by fluorescence lifetime imaging. FASEB J. 2006b ; 20 (12). 2050-7
41. Klucken J, Shin Y, Hyman BT, McLean PJ. A single amino acid substitution differentiates Hsp70-dependent effects on alpha-synuclein degradation and toxicity. Biochem Biophys Res Commun. 2004a ; 325 (1). 367-73
42. Klucken J, Shin Y, Masliah E, Hyman BT, McLean PJ. Hsp70 reduces alpha-synuclein aggregation and toxicity. J Biol Chem. 2004b ; 279 (24). 25497-502
43. Ko HS, Bailey R, Smith WW, Liu Z, Shin JH, Lee YI. CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicity. Proc Natl Acad Sci U S A. 2009 ; 106 (8). 2897-902
44. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet. 1998 ; 18 (2). 106-8
45. Kuzuhara S, Mori H, Izumiyama N, Yoshimura M, Ihara Y. Lewy bodies are ubiquitinated: a light and electron microscopic immunocytochemical study. Acta Neuropathol. 1988 ; 75 (4). 345-53
46. Lai Y, Du L, Dunsmore KE, Jenkins LW, Wong HR, Clark RS. Selectively increasing inducible heat shock protein 70 via TAT-protein transduction protects neurons from nitrosative stress and excitotoxicity. J Neurochem. 2005 ; 94 (2). 360-6
47. Liang J, Clark-Dixon C, Wang S, Flower TR, Williams-Hart T, Zweig R. Novel suppressors of alpha-synuclein toxicity identified using yeast. Hum Mol Genet. 2008 ; 17 (23). 3784-95
48. Liu J, Zhang JP, Shi M, Quinn T, Bradner J, Beyer R. Rab11a and HSP90 regulate recycling of extracellular alpha-synuclein. J Neurosci. 2009 ; 29 (5). 1480-5
49. Lo Bianco C, Shorter J, Regulier E, Lashuel H, Iwatsubo T, Lindquist S. Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease. J Clin Invest. 2008 ; 118 (9). 3087-97
50. Luk KC, Mills IP, Trojanowski JQ, Lee VM. Interactions between Hsp70 and the hydrophobic core of alpha-synuclein inhibit fibril assembly. Biochemistry. 2008 ; 47 (47). 12614-25
51. McLean PJ, Kawamata H, Shariff S, Hewett J, Sharma N, Ueda K. TorsinA and heat shock proteins act as molecular chaperones: suppression of alpha-synuclein aggregation. J Neurochem. 2002 ; 83 (4). 846-54
52. McLean PJ, Klucken J, Shin Y, Hyman BT. Geldanamycin induces Hsp70 and prevents alpha-synuclein aggregation and toxicity in vitro. Biochem Biophys Res Commun. 2004 ; 321 (3). 665-9
53. Meacham GC, Patterson C, Zhang W, Younger JM, Cyr DM. The Hsc70 co-chaperone CHIP targets immature CFTR for proteasomal degradation. Nat Cell Biol. 2001 ; 3 (1). 100-5
54. Meissner WG, Frasier M, Gasser T, Goetz CG, Lozano A, Piccini P. Priorities in Parkinson's disease research. Nat Rev Drug Discov. 2011 ; 10 (5). 377-93
55. Monti B, Gatta V, Piretti F, Raffaelli SS, Virgili M, Contestabile A. Valproic acid is neuroprotective in the rotenone rat model of Parkinson's disease: involvement of alpha-synuclein. Neurotox Res. 2010 ; 17 (2). 130-41
56. Muchowski PJ, Wacker JL. Modulation of neurodegeneration by molecular chaperones. Nat Rev Neurosci. 2005 ; 6 (1). 11-22
57. Nagel F, Falkenburger BH, Tonges L, Kowsky S, Poppelmeyer C, Schulz JB. Tat-Hsp70 protects dopaminergic neurons in midbrain cultures and in the substantia nigra in models of Parkinson's disease. J Neurochem. 2008 ; 105 (3). 853-64
58. Nollen EA, Kabakov AE, Brunsting JF, Kanon B, Hohfeld J, Kampinga HH. Modulation of in vivo HSP70 chaperone activity by Hip and Bag-1. J Biol Chem. 2001 ; 276 (7). 4677-82
59. Outeiro TF, Klucken J, Strathearn KE, Liu F, Nguyen P, Rochet JC. Small heat shock proteins protect against alpha-synuclein-induced toxicity and aggregation. Biochem Biophys Res Commun. 2006 ; 351 (3). 631-8
60. Pan T, Li X, Xie W, Jankovic J, Le W. Valproic acid-mediated Hsp70 induction and anti-apoptotic neuroprotection in SH-SY5Y cells. FEBS Lett. 2005 ; 579 (30). 6716-20
61. Pauli D, Tonka CH, Tissieres A, Arrigo AP. Tissue-specific expression of the heat shock protein HSP27 during Drosophila melanogaster development. J Cell Biol. 1990 ; 111 (3). 817-28
62. Pemberton S, Madiona K, Pieri L, Kabani M, Bousset L, Melki R. Hsc70 protein interaction with soluble and fibrillar alpha-synuclein. J Biol Chem. 2011 ; 286 (40). 34690-9
63. Pirkkala L, Nykanen P, Sistonen L. Roles of the heat shock transcription factors in regulation of the heat shock response and beyond. FASEB J. 2001 ; 15 (7). 1118-31
64. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997 ; 276 (5321). 2045-7
65. Pountney DL, Treweek TM, Chataway T, Huang Y, Chegini F, Blumbergs PC. Alpha B-crystallin is a major component of glial cytoplasmic inclusions in multiple system atrophy. Neurotox Res. 2005 ; 7 (1-2). 77-85
66. Putcha P, Danzer KM, Kranich LR, Scott A, Silinski M, Mabbett S. Brain-permeable small-molecule inhibitors of Hsp90 prevent alpha-synuclein oligomer formation and rescue alpha-synuclein-induced toxicity. J Pharmacol Exp Ther. 2010 ; 332 (3). 849-57
67. Rekas A, Adda CG, Andrew Aquilina J, Barnham KJ, Sunde M, Galatis D. Interaction of the molecular chaperone alphaB-crystallin with alpha-synuclein: effects on amyloid fibril formation and chaperone activity. J Mol Biol. 2004 ; 340 (5). 1167-83
68. Riedel M, Goldbaum O, Schwarz L, Schmitt S, Richter-Landsberg C. 17-AAG induces cytoplasmic alpha-synuclein aggregate clearance by induction of autophagy. PLoS One. 2010 ; 5 (1). e8753
69. Roodveldt C, Bertoncini CW, Andersson A, van der Goot AT, Hsu ST, Fernandez-Montesinos R. Chaperone proteostasis in Parkinson's disease: stabilization of the Hsp70/alpha-synuclein complex by Hip. EMBO J. 2009 ; 28 (23). 3758-70
70. Sarkar S, Davies JE, Huang Z, Tunnacliffe A, Rubinsztein DC. Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein. J Biol Chem. 2007 ; 282 (8). 5641-52
71. Scherzer CR, Eklund AC, Morse LJ, Liao Z, Locascio JJ, Fefer D. Molecular markers of early Parkinson's disease based on gene expression in blood. Proc Natl Acad Sci U S A. 2007 ; 104 (3). 955-60
72. Schulte TW, Neckers LM. The benzoquinone ansamycin 17-allylamino-17- demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol. 1998 ; 42 (4). 273-9
73. Shashidharan P, Good PF, Hsu A, Perl DP, Brin MF, Olanow CW. TorsinA accumulation in Lewy bodies in sporadic Parkinson's disease. Brain Res. 2000 ; 877 (2). 379-81
74. Shen HY, He JC, Wang Y, Huang QY, Chen JF. Geldanamycin induces heat shock protein 70 and protects against MPTP-induced dopaminergic neurotoxicity in mice. J Biol Chem. 2005 ; 280 (48). 39962-9
75. Shin Y, Klucken J, Patterson C, Hyman BT, McLean PJ. The co-chaperone carboxyl terminus of Hsp70-interacting protein (CHIP) mediates alpha-synuclein degradation decisions between proteasomal and lysosomal pathways. J Biol Chem. 2005 ; 280 (25). 23727-34
76. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A. 1998 ; 95 (11). 6469-73
77. St Martin JL, Klucken J, Outeiro TF, Nguyen P, Keller-McGandy C, Cantuti-Castelvetri I. Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra. J Neurochem. 2007 ; 100 (6). 1449-57
78. Tanaka M, Machida Y, Niu S, Ikeda T, Jana NR, Doi H. Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat Med. 2004 ; 10 (2). 148-54
79. Tetzlaff JE, Putcha P, Outeiro TF, Ivanov A, Berezovska O, Hyman BT. CHIP targets toxic alpha-synuclein oligomers for degradation. J Biol Chem. 2008 ; 283 (26). 17962-8
80. Tompkins MM, Hill WD. Contribution of somal Lewy bodies to neuronal death. Brain Res. 1997 ; 775 (1-2). 24-9
81. Uryu K, Richter-Landsberg C, Welch W, Sun E, Goldbaum O, Norris EH. Convergence of heat shock protein 90 with ubiquitin in filamentous alpha-synuclein inclusions of alpha-synucleinopathies. Am J Pathol. 2006 ; 168 (3). 947-61
82. Wakabayashi K, Engelender S, Yoshimoto M, Tsuji S, Ross CA, Takahashi H. Synphilin-1 is present in Lewy bodies in Parkinson's disease. Ann Neurol. 2000 ; 47 (4). 521-3
83. Wang L, Xie C, Greggio E, Parisiadou L, Shim H, Sun L. The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2. J Neurosci. 2008 ; 28 (13). 3384-91
84. Waza M, Adachi H, Katsuno M, Minamiyama M, Sang C, Tanaka F. 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat Med. 2005 ; 11 (10). 1088-95
85. Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci U S A. 1994 ; 91 (18). 8324-8
86. Wickner S, Maurizi MR, Gottesman S. Posttranslational quality control: folding, refolding, and degrading proteins. Science. 1999 ; 286 (5446). 1888-93
87. Winner B, Jappelli R, Maji SK, Desplats PA, Boyer L, Aigner S. In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci U S A. 2011 ; 108 (10). 4194-9
88. Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J. Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur J Epidemiol. 2011 ; 26 (Suppl 1). S1-58
89. Zhou Y, Gu G, Goodlett DR, Zhang T, Pan C, Montine TJ. Analysis of alpha-synuclein-associated proteins by quantitative proteomics. J Biol Chem. 2004 ; 279 (37). 39155-64
90. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004 ; 44 (4). 601-7
91. Zou J, Guo Y, Guettouche T, Smith DF, Voellmy R. Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1. Cell. 1998 ; 94 (4). 471-80
92. Zourlidou A, Payne Smith MD, Latchman DS. HSP27 but not HSP70 has a potent protective effect against alpha-synuclein-induced cell death in mammalian neuronal cells. J Neurochem. 2004 ; 88 (6). 1439-48